Peter J Weber

US Patent:

20040116410, Jun 17, 2004

Filed:

Feb 18, 2003

Appl. No.:

10/344924

Inventors:

Hidetsura Cho - Osaka, JP
Rocco Gogliotti - Pinckney MI, US
Harriet Hamilton - Chelsea MI, US
Alexei Krasutsky - Skokie IL, US
Takeshi Nakamura - Osaka, JP
Hiroki Tada - Osaka, JP
Peter Weber - Canton MI, US

International Classification:

A61K031/551
C07D487/02

US Classification:

514/220000, 540/498000, 540/497000

Abstract:

The invention is novel compounds of formula (I) which exhibit an improved therapeutic index and improved metabolic stability which are useful in the treatment and/or prevention of herpes viral infections. Novel intermediates useful in the synthesis of the final compounds are also part of the invention.

US Patent:

20050250765, Nov 10, 2005

Filed:

Jun 22, 2005

Appl. No.:

11/165139

Inventors:

Hidetsura Cho - Osaka, JP
Rocco Gogliotti - Pinckney MI, US
Harriet Hamilton - Chelsea MI, US
Alexei Krasutsky - Skokie IL, US
Takeshi Nakamura - Osaka, JP
Hiroki Tada - Osaka, JP
Peter Weber - Canton MI, US

International Classification:

A61K031/551
C07D487/02

US Classification:

514220000, 540493000

Abstract:

The invention is novel compounds of formula which exhibit an improved therapeutic index and improved metabolic stability which are useful in the treatment and/or prevention of herpes viral infections. Novel intermediates useful in the synthesis of the final compounds are also part of the invention.

US Patent:

56866011, Nov 11, 1997

Filed:

Feb 18, 1993

Appl. No.:

8/018977

Inventors:

Peter C. Weber - Canton MI

Assignee:

The Penn State Research Foundation - University Park PA

International Classification:

C07H 2104

US Classification:

536 2372

Abstract:

Dominant negative or trans-dominant mutants of viral proteins represent a new and exciting means of antiviral therapy. However, the extreme specificity of a given dominant negative mutant limits its general utility in treating a broad spectrum of viral diseases, since it can typically interfere with the activity of only a single viral polypeptide encoded by a single virus. A dominant negative mutant of a gene encoding promiscuous viral transactivator protein was isolated in an attempt to generate a polypeptide which could inhibit gene expression and, therefore, virus replication nonspecifically. This mutant, a truncated derivative of the gene encoding herpes simplex virus type 1 (HSV-1) regulatory protein ICP0, was found to behave as a powerful repressor of gene expression from an assortment of HSV-1 and non-HSV-1 promoters in transient expression assays. Unexpectedly, it was also capable of inhibiting the replication of both HSV- 1 and a completely unrelated virus, human immunodeficiency virus, in cell culture. Moreover, a derivative of ICP0 with dominant mutant properties similar to that of pD19T can potentially be created by a failure to splice out the intron 2 sequences; translation of this message results in a derivative of ICP0, called ICPOR, which contains all 241 amino acids encoded by exons 1 and 2 plus an additional 21 amino acids derived from translation into the unspliced second intron.